Blueprint Medicines Corp Call to Discuss Data Reported at AACR Transcript
Good afternoon. My name is Tania, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines conference call. (Operator Instructions) Thank you.
Jenna Cohen, you may begin your conference.
Thank you, Tania. Good afternoon, everyone and welcome to Blueprint Medicines conference call to discuss the presentation of initial BLU-945 clinical data at the AACR 2022 Annual Meeting. You can access the press release announcing the data, as well as the slides that we'll be reviewing today by going to the Investors and Media section of our website at www.blueprintmedicines.com.
With me on the call today are Kate Haviland, our Chief Executive Officer; Dr. Fouad Namouni, our President of Research and Development and Dr. David Spigel, the Chief Scientific Officer of the Sarah Cannon Research Institute. Dr. Becker Hewes, our Chief Medical Officer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |